SOLO-1
Two years of an olaparib pill after chemotherapy made a large share of women with BRCA-mutated ovarian cancer long-term survivors.
PFS HR 0.30 at the primary analysis (NEJM 2018). At 7 years, 67.0% of olaparib patients were alive versus 46.5% on placebo (HR 0.55; JCO 2023), the first PARP inhibitor trial with a clinically meaningful overall survival gain in the first-line setting and the basis for the 2018 maintenance approval. Roughly half of olaparib patients remained progression-free at 5 years.
- The treated group had about 70 percent lower chance of the event at any given time (hazard ratio 0.3).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 67 vs 46.5 out of 100 alive at 7 years with Olaparib compared with Placebo; 20.5 more per 100.
- Roughly one extra person helped for every 5 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 45 percent lower chance of the event at any given time (hazard ratio 0.55, likely range 0.4 to 0.76).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Newly diagnosed advanced BRCA-mutated ovarian cancer in response to platinum chemotherapy: olaparib maintenance for 2 years vs placebo. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (BRCA); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
391 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survivalprimary | Olaparib | 260 | — | 0.3 (0.23–0.41) | — | link |
| Placebo | 131 | — | ||||
| Overall survival at 7 years | Olaparib | — | 67% | 0.55 (0.4–0.76) | — | link |
| Placebo | — | 46.5% |
Pages like this
not linked directly; found by shared links- PersonAlan Ashworth
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialPOLO
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialPRIMA / ENGOT-OV26
Shares ctDNA-guided duration of PARP maintenance, PARP, Ovarian cancer.
- TrialPROfound
Shares Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- PersonEileen M. O'Reilly
Shares Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- InstitutionStephenson Cancer Center, OU Health
Shares PARP inhibitors, Olaparib, PARP, Ovarian cancer.